Please use this identifier to cite or link to this item:
Title: Initial experience with golimumab in clinical practice for ulcerative colitis.
Authors: Castro-Laria, Luisa
Argüelles-Arias, Federico
García-Sánchez, Valle
Benítez, José Manuel
Fernández-Pérez, Ramón
Trapero-Fernández, Ana María
Gallardo-Sánchez, Francisco
Pallarés-Manrique, Héctor
Gómez-García, María
Cabello-Tapia, María José
Talavera-Fabuel, Aurora
Bejarano-García, Ana
Leo-Carnerero, Eduardo
Hernández-Martínez, Álvaro
Caunedo-Álvarez, Ángel
Herrerías-Gutiérrez, Juan Manuel
metadata.dc.subject.mesh: Adolescent
Antibodies, Monoclonal
Colitis, Ulcerative
Immunosuppressive Agents
Injections, Subcutaneous
Middle Aged
Retrospective Studies
Treatment Outcome
Tumor Necrosis Factor-alpha
Young Adult
Issue Date: 2016
Abstract: Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis. To research the effectiveness and safety of golimumab in patients with ulcerative colitis in clinical practice. Retrospective study of the effectiveness and safety of golimumab in patients with ulcerative colitis. All patients received golimumab 200 mg subcutaneously at week 0, and golimumab 100 mg subcutaneously at week 2. After the induction treatment, each patient received 50 mg sc. every 4 weeks in patients with body weight less than 80 kg, and 100 mg every 4 weeks in patients with body weight greater than or equal to 80 kg. Study of a group of 23 ulcerative colitis patients, 7 of whom were naive to any anti-TNF therapy, and 16 patients who had previously been treated with an anti-TNF agent other than golimumab (non-naive patients). The average treatment time with golimumab was 14.3 weeks. Globally, withdrawal of corticosteroids was observed in 74% of cases. Clinical response was observed in 85.5% of patients who had not received biological treatment previously, and in patients who had previously received biological treatment the response rate was 75%. In this short study, golimumab seems to be an alternative treatment in naive and non-naive anti-TNF ulcerative colitis patients. It is also a safe therapy, given that there were no adverse effects in the patients studied.
metadata.dc.identifier.doi: 10.17235/reed.2016.4068/2015
ISSN: 1130-0108
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.